Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ZNF384 (F2C1R) Rabbit Monoclonal Antibody #82901

Filter:
  • WB
  • IP

    Product Specifications

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 65-75
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ZNF384 (F2C1R) Rabbit Monoclonal Antibody recognizes endogenous levels of total ZNF384 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ZNF384 protein.

    Background

    Zinc finger protein 384 (ZNF384) was first characterized as a C2H2-type zinc finger protein, functioning as a transcription factor regulating expression of extracellular matrix genes (1). ZNF384 was later shown to also regulate genes involved in cell growth and metastasis (2). ZNF384 has been predominantly studied in B-cell leukemias, particularly B-cell acute lymphoblastic leukemia (B-ALL) (3,4). In these tumors, ZNF384 has aberrant expression, resulting in dysregulation of target genes and mutations resulting in oncogenic fusion proteins (3-5). ZNF384 fusions with EP300, TCF3, TAF15, and CREBBP are the most commonly studied in these cancers (3,4,8). Recent research has focused on mutations and altered expression of ZNF384 in breast cancers (6,7). ZNF384 and its related fusion proteins are being investigated as therapeutic targets in leukemia and other cancers (8).

    Alternate Names

    CAG repeat protein 1; CAGH1; CAGH1A; cancer/testis antigen family 12, member 1a; cancer/testis antigen family 12, member 1b; cancer/testis antigen family 12, member 1c; cancer/testis antigen family 12, member 1d; cancer/testis antigen family 12, member 1e; CAS-interacting zinc finger protein; CIZ; ERDA2; expanded repeat domain, CAG/CTG 2; FLJ59043; NMP4; NP; Nuclear matrix protein 4; Nuclear matrix transcription factor 4; TNRC1; trinucleotide repeat containing 1; Trinucleotide repeat-containing gene 1 protein; Zinc finger protein 384; ZN384; ZNF384

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.